Abstract

Dementia is one of the biggest problems facing health and social services today. Many drugs are claimed to arrest intellectual decline and improve the behaviour disturbance associated with the failing brain. Though called ‘cerebral vasodilators’, or ‘cerebral activators’, their mode of action remains unclear. The clinical assessment of these drugs is difficult and unsatisfactory, as there is no agreement on the goals of treatment or the criteria for success.